Abstract
Buserelin, a potent LH-RH agonist, has been used for the treatment of hormonal disorders such as precocious puberty, endometriosis, cystic mastitis and prostatic carcinoma. Prolonged treatment with buserelin has been known to induce a refractory phase of pituitary desensitization. In the present study, we found that two-week treatment with buserelin strongly suppressed the activities of thymidylate synthetase and thymidine kinase, and markedly reduced the appearance of BrdU-immunoreactive (S-phase) cells in both prostate glands and uteri in male and female adult rats, respectively.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 13-16 |
| Number of pages | 4 |
| Journal | In Vivo |
| Volume | 7 |
| Issue number | 1 |
| State | Published - 1993 |
Keywords
- BrdU
- LH-RH
- endometrium
- prostate gland
- thymidine kinase
- thymidylate synthetase
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
- Cancer Research
- Pharmacology